|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TKTL1 plays a major role in anaerobic glycolysis of tumor cells, leading to destruction of the basal membrane and metastasis as well as in controlling cell cycle.
|
31771043 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data support the hypothesis that TKTL1 and TKTL2 are functional transketolases and represent novel therapeutic targets for diabetes and cancer.
|
30646877 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TKTL1-overexpressing cancer cells exhibit elevated ribose-5-phosphate levels.
|
31175280 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data support the hypothesis that TKTL1 and TKTL2 are functional transketolases and represent novel therapeutic targets for diabetes and cancer.
|
30646877 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
TKTL1-overexpressing cancer cells exhibit elevated ribose-5-phosphate levels.
|
31175280 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TKTL1 inhibition also reduced tumor growth in vivo.
|
29885837 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since TKTL1 represents a drugable target, the EDIM based detection of TKTL1 enables a targeted cancer therapy using the vitamin derivatives oxythiamine or benfo-oxythiamine.
|
28425973 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Epitopes of the apoptosis related protein DNaseX (Apo10) and the pentose-phosphate-pathway associated protein transketolase-like 1 (TKTL1) have been shown to be increased in circulating macrophages of patients with different cancer types including prostate cancer (PC).
|
28726251 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study demonstrates that surgical removal of the primary tumor leads to a significant decrease of Apo10 and TKTL1 expressing macrophages.
|
28726251 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Epitopes of the apoptosis related protein DNaseX (Apo10) and the pentose-phosphate-pathway associated protein transketolase-like 1 (TKTL1) have been shown to be increased in circulating macrophages of patients with different cancer types including prostate cancer (PC).
|
28726251 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Since TKTL1 represents a drugable target, the EDIM based detection of TKTL1 enables a targeted cancer therapy using the vitamin derivatives oxythiamine or benfo-oxythiamine.
|
28425973 |
2017 |
|
Testicular Germ Cell Tumor
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor.
|
28604732 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transketolase-like protein 1 (TKTL1) is an isoform of tranketolase, a key protein in a cancer cell's glucose metabolism that causes rapid cell growth and controls the non-oxidative part of the pentose phosphate pathway (PPP).
|
26650256 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This epigenetic change may enable the natural selection of tumor cells with a metabolic phenotype and thereby provide a potential therapeutic target for a subset of melanoma tumors with elevated TKTL1 expression.
|
26907172 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that high TKTL1 in tumor tissue can lead to poor survival in colorectal cancer.
|
26650256 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Transketolase-like protein 1 (TKTL1) is an isoform of tranketolase, a key protein in a cancer cell's glucose metabolism that causes rapid cell growth and controls the non-oxidative part of the pentose phosphate pathway (PPP).
|
26650256 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive TKTL1 and p63 expression significantly correlated with larger tumor size, deeper invasion, higher TNM stage, and lymph node metastasis (P< 0.05).
|
26406948 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No correlation was observed between cytoplasmatic or nuclear TKTL1 expression and tumor stage, grade or the presence of metastases.
|
25572961 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, TKTL1 activity could be crucial for tumor proliferation and survival.
|
24193262 |
2013 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multifactorial survival analysis showed that TKTL1 overexpression correlated with the patient outcomes in malignant tumors (P = 0.045).
|
22658715 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TKTL1 expression, mitotic rate within the tumor mass, and tumor thickness and its association with clinical outcome.
|
22658715 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As TKTL1 appears to be a valid biomarker for cancer prognosis, the aim of the current study was to correlate its expression with tumor stage, probability of tumor recurrence and survival, in a series of colorectal cancer patients.
|
21980427 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the majority of data on the role of TKTL-1 in human cancer is based upon studies performed with this antibody clone, we subsequently re-evaluated the expression of TKTL-1 in six different cancer cell lines (HeLa, MCF-7, A549, HT-1080, M21 and TF-1).
|
21445778 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To our knowledge, few studies have explored the association between variations in TKTL1 expression in the primary tumor and metastasis formation.
|
21980427 |
2011 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the majority of data on the role of TKTL-1 in human cancer is based upon studies performed with this antibody clone, we subsequently re-evaluated the expression of TKTL-1 in six different cancer cell lines (HeLa, MCF-7, A549, HT-1080, M21 and TF-1).
|
21445778 |
2011 |